An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Triamcinolone (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Flexion Therapeutics
- 08 Aug 2017 According to a Flexion Therapeutics media release, final data readout is expected in the second half of 2018.
- 08 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to a Flexion Therapeutics media release.
- 04 May 2017 According to a Flexion Therapeutics media release, the trial is expected to be fully enrolled in the second half of 2017.